E. Bradley

发表

Erythroleukemia and other hematologic complications of intensive therapy in long‐term survivors of small cell lung cancer

J. Minna, J. Whang‐Peng, P. Bunn, 1982 .

Interleukin 2-activated human lymphocytes exhibit enhanced adhesion to normal vascular endothelial cells and cause their lysis.

J. Bender, N. Damle, L. Doyle, 1987, Journal of immunology.

Interleukin 2-activated human killer cells are derived from phenotypically heterogeneous precursors.

N. Damle, L. Doyle, E. Bradley, 1986, Journal of immunology.

Clinical benefit of INCB7839, a potent and selective ADAM inhibitor, in combination with trastuzumab in patients with metastatic HER2+ breast cancer.

D. Doval, D. Lokanatha, P. Julka, 2010 .

Subcutaneous recombinant interleukin 2 in a dose escalating regimen in patients with metastatic renal cell adenocarcinoma.

G. Hemstreet, D. Ward, M. Konrad, 1990, Cancer research.

Phase I study of cancer therapy with recombinant interleukin-2 administered by intravenous bolus injection

F. Arnett, J. Reuben, E. Hersh, 1989, Biotherapy.

Efficacy of Low-dose Cyclophosphamide and Interleukin-2 in Melanoma

W. Boswell, R. Kempf, H. Shau, 1989 .

A phase I study of recombinant interleukin 2 plus recombinant beta-interferon.

S. Litwin, A. Rudolph, K. Padavic-Shaller, 1988, Cancer research.

A phase I study of recombinant interleukin 2 plus recombinant beta-interferon.

S. Litwin, A. Rudolph, K. Padavic-Shaller, 1988, Cancer research.

Renal cell carcinoma: treatment with recombinant interleukin-2 plus beta-interferon.

A. Rudolph, K. Padavic-Shaller, R. Comis, 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Evidence for tumor reduction in refractory or relapsed B-CLL patients with infusional interleukin-2.

M. Oken, N. Kay, J. Mazza, 1988, Nouvelle revue francaise d'hematologie.

Skeletal manifestations in cutaneous T-cell lymphomas.

P. Bunn, L. Wahl, G. Schechter, 1982, Archives of dermatology.

Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.

Ayalew Tefferi, Z. Estrov, H. Kantarjian, 2010, The New England journal of medicine.

Effectiveness and tolerability of low-dose cyclophosphamide and low-dose intravenous interleukin-2 in disseminated melanoma [corrected].

W. Boswell, R. Kempf, H. Shau, 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Deletion of 3(p14p23) in secondary erythroleukemia arising in long-term survivors of small cell lung cancer.

D. Longo, J. Whang‐Peng, J. Minna, 1988, Journal of the National Cancer Institute.

Cell-mediated inhibition of tumor colony formation in agarose by resting and interleukin 2-stimulated human lymphocytes.

B. Issell, J. Catino, J. Mier, 1985, Cancer research.

A Phase 2 Study of INCB018424, An Oral, Selective JAK1/JAK2 Inhibitor, in Patients with Advanced Polycythemia Vera (PV) and Essential Thrombocythemia (ET) Refractory to Hydroxyurea.

M. Cazzola, T. Barbui, H. Kantarjian, 2009 .

Treatment of metastatic renal cell carcinoma with recombinant interleukin-2 in combination with vinblastine or lymphokine-activated killer cells.

G. Hemstreet, J. Kuebler, D. Ward, 1993, The Journal of urology.

The human tumor colony-forming chemosensitivity assay: A biological and clinical review

B. Issell, E. Bradley, R. Hellman, 2004, Investigational New Drugs.

The development of anti-interleukin-2 antibodies in patients treated with recombinant human interleukin-2 (IL-2)

M. Atkins, J. Mier, R. Dempsey, 1986, Journal of Clinical Immunology.

Low-dose cyclophosphamide and low-dose interleukin-2 for malignant melanoma.

W. Boswell, R. Kempf, H. Shau, 1989, Bulletin of the New York Academy of Medicine.

Therapy of acquired immune deficiency syndrome with recombinant interleukin-2.

P. Volberding, C. Wofsy, E. Bradley, 1987, AIDS research and human retroviruses.

Association between human tumor colony-forming assay results and response of an individual patient's tumor to chemotherapy.

R. Makuch, D. V. Von Hoff, D. D. Hoff, 1981, The American journal of medicine.

Long-Term Follow up and Optimized Dosing Regimen of INCB018424 in Patients with Myelofibrosis: Durable Clinical, Functional and Symptomatic Responses with Improved Hematological Safety.

Z. Estrov, H. Kantarjian, S. Verstovsek, 2009 .

Characterization of JAK2 V617F Allele Burden in Advanced Myelofibrosis (MF) Patients: No Change in V617F:WT JAK2 Ratio in Patients with High Allele Burdens despite Profound Clinical Improvement Following Treatment with the JAK Inhibitor, INCB018424

H. Kantarjian, S. Verstovsek, A. Tefferi, 2008 .

Direct cloning of human neuroblastoma cells in soft agar culture.

J. Trent, R. Makuch, Jeff Trent, 1980, Cancer research.

A phase I‐II study of dacarbazine in combination with outpatient interleukin‐2 in metastatic malignant melanoma

S. Martino, B. Redman, L. Heilbrun, 1990, Cancer.

Effect of fibroblast, lymphoid, and myeloid interferons on human tumor colony formation in vitro.

F. Ruscetti, E. Bradley, 1981, Cancer research.

A phase I trial of intraperitoneal recombinant interleukin 2 in patients with ovarian carcinoma

J. Gabrilove, P. Chapman, R. Mertelsmann, 1988, Investigational New Drugs.

Pharmacokinetics of recombinant interleukin 2 in humans.

P W Mansell, E. Hersh, R. Mertelsmann, 1990, Cancer research.

Interferon-γ induced by administration of recombinant interleukin-2 to patients with cancer: Kinetics, dose dependence, and correlation with physiological and therapeutic response

E. Hersh, A. Rudolph, E. Groves, 1992 .

The JAK Inhibitor, INCB018424, Demonstrates Durable and Marked Clinical Responses in Primary Myelofibrosis (PMF) and Post-Polycythemia/Essential Thrombocythemia Myelofibrosis (Post PV/ETMF).

H. Kantarjian, J. Cortes, S. Verstovsek, 2008 .

Direct cloning of human parathyroid hyperplasia cells in soft-agar culture.

D. V. Von Hoff, M. Brennan, C. Reichert, 1980, Cancer research.

Establishment and characterization of a panel of human lung cancer cell lines.

H. Baker, J. Holden, B. Campling, 1992, Cancer.

Durable Responses with the JAK1/ JAK2 Inhibitor, INCB018424, In Patients with Polycythemia Vera (PV) and Essential Thrombocythemia (ET) Refractory or Intolerant to Hydroxyurea (HU)

M. Cazzola, T. Barbui, H. Kantarjian, 2010 .

Phase I trial of recombinant interleukin-2 and cyclophosphamide: augmentation of cellular immunity and T-cell mitogenic response with long-term administration of rIL-2.

J. Kolitz, K. Welte, V. J. Merluzzi, 1988, Journal of biological response modifiers.

Biotechnology products in cancer therapy: a colloquium.

J. Weinstein, E. Borden, R. Metzgar, 1988, Cancer Research.

Inhibition of differentiation and proliferation of colony-stimulating factor-induced clonal growth of normal human marrow cells in vitro by retinoic acid.

F. Ruscetti, H. Steinberg, K. Blaine, 1983, Journal of the National Cancer Institute.

Erythroleukemia and other hematologic complications of intensive therapy in long-term survivors of small cell lung cancer.

J. Minna, J. Whang‐Peng, P. Bunn, 1982, Cancer.

Phase I trial of recombinant interleukin-2 and recombinant beta-interferon in refractory neoplastic diseases.

A. Rudolph, A. Scalzo, B. Poiesz, 1989, Journal of biological response modifiers.

Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.

Z. Estrov, H. Kantarjian, S. Verstovsek, 2010, The New England journal of medicine.

INCB018424, a Selective JAK1/2 Inhibitor, Significantly Improves the Compromised Nutritional Status and Frank Cachexia in Patients with Myelofibrosis (MF).

H. Kantarjian, S. Verstovsek, R. Mesa, 2008 .